Mosaic ImmunoEngineering (OTCMKTS:CPMV – Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.03) EPS for the quarter, Zacks reports.
Mosaic ImmunoEngineering Stock Performance
OTCMKTS:CPMV opened at $0.70 on Friday. The firm has a market cap of $5.03 million, a price-to-earnings ratio of -6.95 and a beta of -0.78. The company’s 50-day moving average is $0.58 and its two-hundred day moving average is $0.58. Mosaic ImmunoEngineering has a 12-month low of $0.25 and a 12-month high of $1.05.
About Mosaic ImmunoEngineering
Mosaic ImmunoEngineering (OTCMKTS:CPMV) is a development-stage biotechnology company focused on advancing immunotherapies and vaccine candidates through its proprietary nanoparticle platform. The company leverages virus-like particles derived from the cowpea mosaic virus (CPMV) to serve as both antigen carriers and immune stimulators, aiming to enhance the magnitude and durability of immune responses. By engineering these plant-based VLPs to display target antigens or adjuvant properties, Mosaic ImmunoEngineering seeks to create differentiated candidates for oncology indications and infectious disease prevention.
Operating out of the United States, Mosaic ImmunoEngineering is currently in preclinical stages of development.
See Also
Receive News & Ratings for Mosaic ImmunoEngineering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mosaic ImmunoEngineering and related companies with MarketBeat.com's FREE daily email newsletter.
